Trial
NCT00571519
Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Daiichi Sankyo
Collaborators
—
Condition
Type 2 Diabetes Mellitus
Intervention
Rivoglitazone HCl
Why stopped
DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-26